" /> Bexmarilimab - CISMeF





Preferred Label : Bexmarilimab;

NCIt synonyms : Anti-stabilin-1 Monoclonal Antibody FP-1305;

NCIt definition : A monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1), with potential immunomodulatory and antineoplastic activities. Upon administration, bexmarilimab targets and binds to CLEVER-1 that is expressed on tumor endothelial cells. This prevents the recruitment, infiltration and attachment of tumor-associated macrophages (TAMs) at the tumor site. By preventing the binding of TAMs to tumor cells, the infiltration of activated T-regulatory cells (Tregs) to the tumor and the TAM-mediated immune suppression is abrogated, leading to the polarization of TAM from the immunosuppressive M2 macrophages to the anti-inflammatory and immunostimulatory M1 macrophages. This leads to the activation of the immune system, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response and inhibition of tumor cell growth and metastasis. CLEVER-1 is an endothelial cell surface molecule involved in immune suppression, cancer growth and metastasis.;

UNII : SA0O2AK3LA;

CAS number : 2259301-27-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2259301-27-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Clevegen;

Molecule name : FP 1305; FP-1305;

NCI Metathesaurus CUI : CL951430;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.